Scailyte

Scailyte is an ETH spin-off based on pioneering research from Manfred Claassen, Professor for Computational Biology at ETH Zurich. The company has developed the first discovery engine that applies artificial intelligence to single-cell data in order to identify cellular biomarkers. It can intelligently crunch hundreds of millions of data points provided by millions of cells from both sick and healthy people in a matter of a few days. The artificial intelligence is trained to identify patterns that point to specific diseases on the cellular level. Scailyte has already successfully identified a signature for the skin cancer Cutaneous T-Cell Lymphoma (CTCL) and patented the biomarker that allows very early diagnosis. The company is now working on turning this finding into a diagnostic test. Furthermore, the discovery of two more biomarkers including an early diagnostic for Endometriosis, a condition that impacts over 170 million women worldwide, is well underway.
Dr. Peter Nesterov about Verve Ventures
Being one of Verve Ventures' portfolio companies has significantly increased our visibility in the startup community.
Founders / Management Dr. Peter Nestorov, Prof. Dr. Manfred Claassen
Sectors Health & Bio, Single Cell Technology, Artificial Intelligence
Located in Switzerland
Co-Investors Swisscom Ventures
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.